Silexion Therapeutics Corp (SLXN) concluded trading on Wednesday at a closing price of $1.03, with 66.8 million shares of worth about $68.8 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -68.99% during that period and on April 23, 2025 the price saw a gain of about 46.51%. Currently the company’s common shares owned by public are about 8.69M shares, out of which, 7.91M shares are available for trading.
Stock saw a price change of 30.38% in past 5 days and over the past one month there was a price change of -8.04%. Year-to-date (YTD), SLXN shares are showing a performance of -48.76% which decreased to -98.93% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.57 but also hit the highest price of $122.02 during that period. The average intraday trading volume for Silexion Therapeutics Corp shares is 13.43 million. The stock is currently trading 14.16% above its 20-day simple moving average (SMA20), while that difference is down -3.08% for SMA50 and it goes to -94.31% lower than SMA200.
Silexion Therapeutics Corp (NASDAQ: SLXN) currently have 8.69M outstanding shares and institutions hold larger chunk of about 7.18% of that.
The stock has a current market capitalization of $8.95M and its 3Y-monthly beta is at 0.24. It has posted earnings per share of -$19.98 in the same period. It has Quick Ratio of 0.64. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for SLXN, volatility over the week remained 20.90% while standing at 14.28% over the month.
Analysts are in expectations that Silexion Therapeutics Corp (SLXN) stock would likely to be making an EPS of 0 in the current quarter, while forecast for next quarter EPS is 0 and it is 0 for next year. For the current quarter EPS, analysts have given the company a lowest target 0 which is 0 at the higher side of the target for the same. Stock’s fiscal year EPS is expected to rise by 96.36% while it is estimated to decrease by -36.46% in next year. EPS is likely to grow at an annualized rate of 59.98% for next 5-years, compared to annual growth of -286.10% made by the stock over the past 5-years.
